BWL
ZNTL icon

Bogart Wealth LLC’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bogart Wealth LLC’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-125
Closed -$2.51K – 1128
2023
Q3 		$2.51K Hold
125
– – ﹤0.01% 849
2023
Q2 		$3.53K Buy
+125
New +$3K ﹤0.01% 789

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bogart Wealth LLC's ZNTL Position: Q4 2023 in Review

Bogart Wealth LLC sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 125 shares — an estimated $2.51K sold.

Bogart Wealth LLC first reported a position in ZNTL in Q2 2023 and held it in 2 quarters. The position peaked at $3.53K in Q2 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • Bogart Wealth LLC reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Bogart Wealth LLC sold 125 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $2.51K.
  • Bogart Wealth LLC first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Bogart Wealth LLC's Zentalis Pharmaceuticals position peaked at $3.53K in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Bogart Wealth LLC's 13F filing for Q4 2023, filed 7 Feb 2024.